TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04903899

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
Study: NCT05213442

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.
Description: Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires).
Study: NCT05097937

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity percutaneous electrolysis
Description: A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity percutaneous electrolysis
Description: Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
Study: NCT06099119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: creon 35.000 Ph.U (R)
Description: Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.

Intervention type: OTHER
Group type: OTHER
Intervention: Best Standarard of Care
Description: Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
Study: NCT06547788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Description: Mitral valve repair with creation of an 8 mm inter-atrial shunt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Description: Mitral valve repair with creation of an 8 mm inter-atrial shunt
Study: NCT05379153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Undergo vaginal fractional CO2 laser therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo placebo procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study: NCT05196451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation based on CBT principles
Description: Cf. arm description
Study: NCT06222814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
Description: ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
Description: ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
Study: NCT05080738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Extremity Home Exercises
Description: The exercises will be performed as follows:~1. Stretching exercises: It will be applied in the form of 10 seconds\*10 repetitions for fingers, wrists, elbows and shoulders.~2. Strengthening exercises: It will be applied as 2 sets\*10 repetitions for fingers, wrists, elbows and shoulders.
Study: NCT06010628

Intervention type: DRUG
Group type: OTHER
Intervention: Tenecteplase
Description: intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
Study: NCT05524727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept-guided, personalized, motor-cognitive training by means of an exergame
Description: 12 weeks, two times per week for 30-40min
Study: NCT05889962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block
Description: Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
Study: NCT05367505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFuse-3D implant
Description: The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
Study: NCT06234553

Intervention type: PROCEDURE
Intervention: surgery of pituitary adenomas
Description: evaluate pathological type and treatment effect after treatment
Study: NCT05000047

Intervention type: DEVICE
Intervention: 3D ear scanner
Description: A commercially-available ear scanning device used according to standard of care. A hand-held device is used and is considered less invasive than conventional earmold impressions.

Intervention type: OTHER
Intervention: Conventional silicon ear impressions
Description: A two part silicon impression material that is used to fill the ear and produce a physical cast of the ear canal. The procedure is standard of care.
Study: NCT06028490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection-1
Description: subcutaneous，dose\*1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection-2
Description: subcutaneous，dose\*2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous，dose\*2
Study: NCT05852145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stevioside
Description: 355 ml of tea lemon flavor added with 2.2 gr. of stevioside should be drunk~* Salivary pH will be collected at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be determined at 0 and 120 minutes later.~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 and 120 minutes later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stevioside
Description: 355 ml of tea lemon flavor added with 2.2 gr. of stevioside should be drunk~* Salivary pH will be collected at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be determined at 0 and 120 minutes later.~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 and 120 minutes later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stevioside
Description: 355 ml of tea lemon flavor added with 2.2 gr. of stevioside should be drunk~* Salivary pH will be collected at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later.~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be determined at 0 and 120 minutes later.~* Operative Taxonomic Units of dental biofilm will be analyzed at 0 and 120 minutes later.
Study: NCT04729205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
Study: NCT04970719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: 200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: 200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
Study: NCT05219838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 will be administered per dose and schedule specified in the arm description.
Study: NCT04943471

Intervention type: OTHER
Intervention: Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire
Description: Questionnaire
Study: NCT04547777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT
Description: D2C7-IT intratumoral infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2141-V11
Description: 2141-11 intratumoral infusion
Study: NCT06360211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration
Study: NCT04708496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria.
Study: NCT05897827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLANTS
Description: PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMAILS
Description: The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
Study: NCT05745233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
Study: NCT05844085

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-polar lipids
Description: The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No lipids
Description: The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polar lipids low
Description: The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polar lipids high
Description: The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
Study: NCT06299267

Intervention type: OTHER
Group type: OTHER
Intervention: dual task conditions
Description: dual task conditions on manual skill tests
Study: NCT05979584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Fibrin Plasma
Description: Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
Study: NCT05717621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTD-101 ointment
Description: Self-administration of VTD-101 ointment (Decitabine ointment)
Study: NCT06017908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation through Virtual Reality
Description: The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation through Virtual Reality
Description: The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
Study: NCT05048056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 Regimen 1- subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 Regimen 1- subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: AK120 Regimen 2- subcutaneous injection every 2 weeks
Study: NCT06499389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic and early intensive instrumental respiratory physiotherapy for patients undergoing difficult ventilatory weaning
Description: Patients randomized to this group will receive 3 sessions per day of intensive early respiratory physiotherapy with instrumental techniques from randomization to day 7, before and after any extubation. The strategy will be applied until day 7 of randomization, regardless of the patient's status (intubated or not).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized standard-of-care respiratory physiotherapy
Description: Patients in this group will receive standardized and protocolized respiratory physiotherapy to reproduce the usual practices of non-expert centers,1 to 2 sessions of manual respiratory physiotherapy (not assisted by an instrumental technique) per day until the day of successful extubation, or until day 7 if necessary
Study: NCT06547307

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine 2 mg
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine 4 mg
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine 0 mg
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.